| Literature DB >> 27418651 |
Hans-Josef Feistritzer1, Gert Klug1, Sebastian J Reinstadler1, Martin Reindl1, Agnes Mayr2, Johannes Mair1, Bernhard Metzler3.
Abstract
BACKGROUND: Measurement of biomarkers provides a cost-effective and widely available method to estimate cardiac dysfunction and clinical outcome of patients with acute myocardial infarction (AMI). SOURCES OF DATA: PubMed entries with terms 'myocardial infarction' and the respective biomarker. AREAS OF AGREEMENT: Cardiac troponins and natriuretic peptides are closely related to left ventricular dysfunction and the occurrence of adverse clinical events following AMI. AREAS OF CONTENTION: The incremental value of novel biomarkers is controversial. FUTURE DIRECTIONS: The combination of traditional and novel biomarkers might further improve risk stratification of patients with AMI. SEARCH STRATEGY: We searched all entries on the PubMed database with the MeSH terms 'myocardial infarction' and 'cardiac troponins', 'natriuretic peptides', 'copeptin', galectin-3', 'corin', 'fetuin-A', 'adiponectin' and 'microRNA'.Entities:
Keywords: acute myocardial infarction; biomarkers; cardiac function; prognosis
Mesh：
Substances：
Year: 2016 PMID： 27418651 DOI： 10.1093/bmb/ldw027
Source DB: PubMed Journal: Br Med Bull ISSN： 0007-1420 Impact factor: 4.291